Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$51.45 USD
+0.18 (0.35%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $51.39 -0.06 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BHVN 51.45 +0.18(0.35%)
Will BHVN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BHVN
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
Other News for BHVN
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), PROCEPT BioRobotics (PRCT) and Travere Therapeutics (TVTX)
Buy Rating Affirmed for Biohaven on Promising SMA Treatment and Convenient Administration Advantage
Buy Rating on Biohaven: Breakthrough Potential with T-Alfa in SMA Treatment
RBC says Scholar Rock 'win' in SMA has favorable Biohaven implications
12 Health Care Stocks Moving In Monday's Pre-Market Session